- Home
- / Adagene
Adagene
Stock Price
$3.1
2024-10-29
Market Capitalization
$137.2 M
2024-10-29
Revenue
$18.1 M
FY, 2023
Adagene Summary
Company Summary
- Overview
- Adagene is an antibody discovery and development biotechnology company specializing in oncology immunotherapy. It is creating a pipeline of mono-specific and bi-specific antibody therapeutics with the help of computational biology and artificial intelligence.
- Type
- Public
- Status
- Active
- Founded
- 2012
- HQ
- Suzhou, CN | view all locations
- Website
- http://www.adagene.com/
- Cybersecurity rating
Table of Contents
Key People
Peter Luo, Chairman of the Board of Directors
Jc Xu, Chief Scientific Officer
Qinghai Zhao, Chief Manufacturing Officer
Operating MetricsView all
IND-Enabling Stage Products
6
Q3, 2020
Phase I Trials Products
4
Q3, 2020
LocationsView all
3 locations detected
Suzhou, Jiangsu Sheng HQ
China
4f, building c14, no, 218 Xinghu St, Wuzhong Qu
San Diego, CA
United States
10179 Huennekens St
San Francisco, CA
United States
315 Montgomery St, San Francisco
Adagene Financials
Summary Financials
- Net income (H1, 2024)
- ($17.0M)
- Cash (H1, 2024)
- $95.7M
- EBIT (H1, 2024)
- ($18.3M)
- Enterprise value
- $62.1M